Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system.
Renovanz M, Kurz SC, Rieger J, Walter B, Becker H, Hille H, Bombach P, Rieger D, Grosse L, Häusser L, Skardelly M, Merk DJ, Paulsen F, Hoffmann E, Gani C, Neumann M, Beschorner R, Rieß O, Roggia C, Schroeder C, Ossowski S, Armeanu-Ebinger S, Gschwind A, Biskup S, Schulze M, Fend F, Singer S, Zender L, Lengerke C, Brucker SY, Engler T, Forschner A, Stenzl A, Kohlbacher O, Nahnsen S, Gabernet G, Fillinger S, Bender B, Ernemann U, Öner Ö, Beha J, Malek HS, Möller Y, Ruhm K, Tatagiba M, Schittenhelm J, Bitzer M, Malek N, Zips D, Tabatabai G. Renovanz M, et al. Among authors: schulze m. Neurooncol Adv. 2023 Feb 14;5(1):vdad012. doi: 10.1093/noajnl/vdad012. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 36915613 Free PMC article.
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A, Battke F, Hadaschik D, Schulze M, Weißgraeber S, Han CT, Kopp M, Frick M, Klumpp B, Tietze N, Amaral T, Martus P, Sinnberg T, Eigentler T, Keim U, Garbe C, Döcker D, Biskup S. Forschner A, et al. Among authors: schulze m. J Immunother Cancer. 2019 Jul 12;7(1):180. doi: 10.1186/s40425-019-0659-0. J Immunother Cancer. 2019. PMID: 31300034 Free PMC article. Clinical Trial.
Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options.
Bitzer M, Ostermann L, Horger M, Biskup S, Schulze M, Ruhm K, Hilke F, Öner Ö, Nikolaou K, Schroeder C, Riess O, Fend F, Zips D, Hinterleitner M, Zender L, Tabatabai G, Beha J, Malek NP. Bitzer M, et al. Among authors: schulze m. JCO Precis Oncol. 2020 Mar 30;4:PO.19.00359. doi: 10.1200/PO.19.00359. eCollection 2020. JCO Precis Oncol. 2020. PMID: 32923905 Free PMC article. Review.
The question of WGS's clinical utility remains unanswered.
Battke F, Schulte B, Schulze M, Biskup S. Battke F, et al. Among authors: schulze m. Eur J Hum Genet. 2021 May;29(5):722-723. doi: 10.1038/s41431-021-00823-y. Epub 2021 Feb 17. Eur J Hum Genet. 2021. PMID: 33597733 Free PMC article. No abstract available.
Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma.
Bitzer M, Spahn S, Babaei S, Horger M, Singer S, Schulze-Osthoff K, Missios P, Gatidis S, Nann D, Mattern S, Scheble V, Nikolaou K, Armeanu-Ebinger S, Schulze M, Schroeder C, Biskup S, Beha J, Claassen M, Ruhm K, Poso A, Malek NP. Bitzer M, et al. Among authors: schulze osthoff k, schulze m. NPJ Precis Oncol. 2021 Sep 3;5(1):80. doi: 10.1038/s41698-021-00220-0. NPJ Precis Oncol. 2021. PMID: 34480077 Free PMC article.
NOTCH3 missense mutations as predictor of long-term response to gemcitabine in a patient with epithelioid hemangioendothelioma.
Schmidt M, Mattern S, Singer S, Schulze M, Biskup S, Krumm P, Lauer UM, Zender L, Hinterleitner C, Hinterleitner M. Schmidt M, et al. Among authors: schulze m. J Cancer Res Clin Oncol. 2023 Aug;149(9):6753-6757. doi: 10.1007/s00432-023-04598-1. Epub 2023 Feb 7. J Cancer Res Clin Oncol. 2023. PMID: 36749424 Free PMC article. Review.
1,428 results